PD-L1 is upregulated in CD163+ tonsillar macrophages from children undergoing EBV primary infection
Authors:
Open Access
- 14 November 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 940910
Abstract
Epstein–Barr Virus (EBV) is a tumor associated virus that modulates not only the infected cells but also innate and adaptive immunity. Macrophages play a key role in tumor development and progression. Particularly, the M2 phenotype (CD163) with anti-inflammatory activity contributes to a favorable microenvironment for tumor development while the M1 (CD68) proinflammatory phenotype contributes to a restrictive one. In the context of pediatric EBV infection, little is known about macrophage contribution to PD-L1 expression, a molecule involved in immune exhaustion. We studied tonsils of primary infected (PI), healthy carriers (HC), reactivated (R), and not infected (NI) pediatric patients. Positive correlations were demonstrated for CD68+PD-L1+ in R and for CD163+PD-L1+ only in PI. Furthermore, CD163+PD-L1+ cell numbers were higher than PD-L1+CD68+ in PI patients. In addition, a positive correlation between PD-L1+CD163+ cells and LMP1 viral latent protein was observed in PI patients, and a positive correlation between PD-L1+CD68+ cells and BMRF1 lytic antigen was demonstrated. A positive correlation between TGF-β and PD-L1 expression was demonstrated in HC patients. Our findings indicate that EBV’s lytic and latent antigens might be regulating macrophages’ PD-L1 expression, particularly in PI patients, whereas, surprisingly, only TGF-β could be related to total PD-L1 upregulation. Given the relevance of macrophages and the PD-1/PD-L1 pathway in tumor progression and survival, more studies in early EBV infection could help to develop EBV-associated tumor therapies.Keywords
Funding Information
- Agencia Nacional de Promoción Científica y Tecnológica (PICT 2015 1533, PICT 2017 1554, PICT 2018 0966)
This publication has 28 references indexed in Scilit:
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphomaJournal of Hematology & Oncology, 2016
- Analysis of Epstein-Barr virus infection models in a series of pediatric carriers from a developing countryScientific Reports, 2016
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapyOncotarget, 2014
- The interplay between Epstein–Barr virus and B lymphocytes: implications for infection, immunity, and diseaseImmunologic Research, 2014
- Epstein-Barr virus-associated lymphoproliferative disordersPostępy Higieny I Medycyny Doświadczalnej, 2013
- EBV primary infection in childhood and its relation to B-cell lymphoma development: A mini-review from a developing regionInternational Journal of Cancer, 2012
- Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological PatternsJournal of Clinical Microbiology, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapyEuropean Journal of Cancer, 2006
- Epstein–Barr virus-associated malignancies: epidemiologic patterns and etiologic implicationsCritical Reviews in Oncology/Hematology, 2000